Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

Despite a far lower partial response rate in colorectal cancer than in lung cancer, Amgen plans to expand its colorectal trials and gear up for combination studies of closely watched KRAS inhibitor AMG 510, citing an impressive stable disease signal.

At the European Society for Medical Oncology (ESMO) meeting on Saturday, Amgen Inc. (NASDAQ:AMGN) reported one of

Read the full 578 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE